Clinical Trials Browser

Leukoplakia, Oral

NCT07441681 2026-03-02

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07432087 2026-02-25

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 3 Not yet recruiting

246 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07402538 2026-02-11

Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma

Phase 3 Not yet recruiting

184 enrolled

Head & Neck

Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07385079 2026-02-03

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

412 enrolled

Head & Neck

Nasopharyngeal Neoplasms

NCT07371897 2026-01-28

SHINE

Phase 3 Not yet recruiting

154 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

418 enrolled

Head & Neck

Nasopharyngeal Neoplasms

NCT07320690 2026-01-06

Neo-Margin

Phase 3 Not yet recruiting

356 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07264075 2025-12-04

ILLUMINE

Phase 3 Not yet recruiting

780 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07238569 2025-11-20

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

516 enrolled

Head & Neck

Nasopharyngeal Cancinoma (NPC)

NCT07239674 2025-11-20

DELTA

Phase 3 Not yet recruiting

646 enrolled

Head & Neck

Thyroid Diseases

NCT07125755 2025-08-15

Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

Phase 3 Not yet recruiting

386 enrolled

Head & Neck

Squamous Cell Cancer of Head and Neck (SCCHN)

NCT07072000 2025-07-18

Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity

Phase 3 Not yet recruiting

550 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06957938 2025-05-08

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma

Phase 3 Not yet recruiting

168 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT06900218 2025-04-02

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

664 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06775756 2025-01-15

Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer

Phase 3 Not yet recruiting

474 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06647563 2024-10-18

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Phase 3 Not yet recruiting

355 enrolled

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT06486220 2024-07-03

PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized Clinical Trial.

Phase 3 Not yet recruiting

96 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06095167 2023-10-23

Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC

Phase 3 Not yet recruiting

476 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05780294 2023-03-22

A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC

Phase 3 Not yet recruiting

132 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05468554 2022-10-19

METHYR

Phase 3 Not yet recruiting

160 enrolled

Head & Neck

Thyroid Neoplasms

NCT04215510 2021-02-23

Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT

Phase 3 Not yet recruiting

286 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03529279 2018-05-18

CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy

Phase 3 Not yet recruiting

1,324 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03503136 2018-05-11

NX-NPC

Phase 3 Not yet recruiting

632 enrolled

Head & Neck

Nasopharyngeal Carcinoma

Clinical Trials

PDT CALCI HOL

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

SHINE

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Neo-Margin

ILLUMINE

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

DELTA

Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized Clinical Trial.

Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC

A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC

METHYR

Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT

CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy

NX-NPC